SkinBioTherapeutics (SBTX)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

0.000p
   
  • Closing Price Chg:
    -1.00p
  • 52 Week High: 26.00p
  • 52 Week Low: 10.00p
  • Currency: UK Pounds
  • Shares Issued: 258.78m
  • Volume: 0
  • Beta: 0.01

SBTX Overview

SkinBioTherapeutics is a life science company focused on skin health. The Company’s proprietary platform technology, SkinBiotix®, is based upon discoveries made by CSO Dr. Catherine O’Neill and Professor Andrew McBain at The University of Manchester.

1 Day Chart

1 Day Chart

6 Month Chart

6 Month Chart
Barclays logo

Digital Look Charts Sponsored by Barclays Stockbrokers

Financials

Latest F'cast
Div Yield 0.0% 0.0%
Div Cover n/a n/a
Op Mrgn -240.4% n/a
ROCE n/a  
Latest F'cast
P/E n/a n/a
PEG n/a n/a
Pr/Revenue 30.0 n/a
Pr/Book 12.2  
Latest F'cast
Revenue 815.3% n/a
PBT n/a n/a
EPS n/a n/a
DPS n/a n/a

SBTX Fundamentals

Year Ending Revenue (£m) Pre-tax (£m) EPS P/E PEG EPS Grth. Div Yield
30-Jun-20 n/a (1.62) (1.17)p n/a n/a n/a n/a 0.0%
30-Jun-21 n/a (1.50) (0.01)p n/a n/a n/a n/a 0.0%
30-Jun-22 0.07 (2.99) (1.78)p n/a n/a n/a n/a 0.0%
30-Jun-23 0.13 (3.01) (1.72)p n/a n/a n/a n/a 0.0%
30-Jun-24 1.21 (2.95) (1.54)p n/a n/a n/a n/a 0.0%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

SBTX Company Announcements

FY Trading Update 14-Aug-2025 07:00 RNS
Croda Commercial Launch Progressing as Expected 30-Jun-2025 07:00 RNS
Notice of IMC Shareholder Presentation 27-Jun-2025 07:00 RNS

SBTX ShareCast News

SkinBioTherapeutics revenue rises fourfold, stil... 14-Aug-2025 ShareCast
SkinBioTherapeutics inks Superdrug deal, raises ... 16-Jun-2025 ShareCast
SkinBioTherapeutics shares jump on acquisition o... 11-Oct-2024 ShareCast

Latest SBTX Director Deals

No deals were found in the last 28 days.

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 3: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 4: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 5: Forecast figures based on normalised accounts.

 

SBTX Market Data

Currency UK Pounds
Share Price 14.00p
Closing Price Change -1.00p
% Change 0.00 %
52 Week High 26.00p
52 Week Low 10.00p
Volume 0
Shares Issued 258.78m
Beta 0.01

SBTX Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
71.02% below the market average71.02% below the market average71.02% below the market average71.02% below the market average71.02% below the market average
76.74% below the sector average76.74% below the sector average76.74% below the sector average76.74% below the sector average76.74% below the sector average
Price Trend
37.81% below the market average37.81% below the market average37.81% below the market average37.81% below the market average37.81% below the market average
15.56% above the sector average15.56% above the sector average15.56% above the sector average15.56% above the sector average15.56% above the sector average
Income Not Available
Growth
49.88% above the market average49.88% above the market average49.88% above the market average49.88% above the market average49.88% above the market average
73.33% above the sector average73.33% above the sector average73.33% above the sector average73.33% above the sector average73.33% above the sector average

SBTX Dividends

No dividends found

Trades for 15-Aug-2025

Time Volume / Share Price
15:20 1,500 @ 14.25p
15:13 21,000 @ 14.40p
14:47 10,000 @ 14.25p
14:45 15 @ 14.25p
14:44 100,000 @ 14.25p

SBTX Key Personnel

CEO Stuart Ashman
CFO Manprit Singh Randhawa

Top of Page